Program
AEF0217
A development code. Also written as “AEF0217 100 µg” and “AEF0217 300 µg”.
Its studies are mostly in Down Syndrome, led by Aelis Farma.
Furthest: phase 2, since Jan 11, 20233 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aelis Farma | 31 open or running | phase 2since Jan 11, 2023 | Dec 7, 2021 | Dec 31, 2027phase 2 · NCT07334912 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 7, 2021First study: phase 1 study in Safety, Tolerability, Pharmacokinetics of AEF0217First studyNCT05170737 · 68 enrolled · Spain
- Jan 11, 2023Phase 2 study in Down SyndromeNCT05748405 · 40 enrolled · Spain
- Nov 20, 2025Phase 2 study in Down SyndromeNCT07334912 · 188 planned · France, Italy, Spain
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Down SyndromeNCT07334912
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07334912Down Syndrome · France, Italy, Spain | 2 | Recruiting | Dec 31, 2027 | 188 |
| NCT05748405Down Syndrome · Spain | 2 | Completed | Oct 7, 2024 | 40 |
| NCT05170737Safety, Tolerability, Pharmacokinetics of AEF0217 · Spain | 1 | Completed | Jun 28, 2022 | 68 |
How it is read
Names in the registry
- “AEF0217”, 2 entries
- “AEF0217 100 µg”, 1 entry
- “AEF0217 300 µg”, 1 entry
Codes read as this program: AEF0217.
Conditions, from the studies’ own filings
- Down Syndrome, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.